Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1266015.RAKsJ2qbIpu0Cs3WuyFjON_C5qpQ_75Cu5YE8kvIDlknY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1266015.RAKsJ2qbIpu0Cs3WuyFjON_C5qpQ_75Cu5YE8kvIDlknY130_assertion type Assertion NP1266015.RAKsJ2qbIpu0Cs3WuyFjON_C5qpQ_75Cu5YE8kvIDlknY130_head.
- NP1266015.RAKsJ2qbIpu0Cs3WuyFjON_C5qpQ_75Cu5YE8kvIDlknY130_assertion description "[Overall, the IL1?/IL1R/MYD88/IL6 pathway may be responsible for the reduced antitumor efficacy of erlotinib and other EGFRIs, and blockade of IL1 signaling may improve the efficacy of EGFRIs in the treatment of HNSCC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1266015.RAKsJ2qbIpu0Cs3WuyFjON_C5qpQ_75Cu5YE8kvIDlknY130_provenance.
- NP1266015.RAKsJ2qbIpu0Cs3WuyFjON_C5qpQ_75Cu5YE8kvIDlknY130_assertion evidence source_evidence_literature NP1266015.RAKsJ2qbIpu0Cs3WuyFjON_C5qpQ_75Cu5YE8kvIDlknY130_provenance.
- NP1266015.RAKsJ2qbIpu0Cs3WuyFjON_C5qpQ_75Cu5YE8kvIDlknY130_assertion SIO_000772 25712126 NP1266015.RAKsJ2qbIpu0Cs3WuyFjON_C5qpQ_75Cu5YE8kvIDlknY130_provenance.
- NP1266015.RAKsJ2qbIpu0Cs3WuyFjON_C5qpQ_75Cu5YE8kvIDlknY130_assertion wasDerivedFrom befree-2016 NP1266015.RAKsJ2qbIpu0Cs3WuyFjON_C5qpQ_75Cu5YE8kvIDlknY130_provenance.
- NP1266015.RAKsJ2qbIpu0Cs3WuyFjON_C5qpQ_75Cu5YE8kvIDlknY130_assertion wasGeneratedBy ECO_0000203 NP1266015.RAKsJ2qbIpu0Cs3WuyFjON_C5qpQ_75Cu5YE8kvIDlknY130_provenance.